A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Shubham PantJohanna Bendell

Abstract

Notch signalling regulates stem cell development and survival and is deregulated in multiple malignancies. LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein. We report the first-in-human phase I trial of LY900009. Dose escalation (Part A) was performed in cohorts of three advanced cancer patients using a modified continual reassessment method and dose confirmation (Part B) was performed in ovarian cancer patients. LY900009 was taken orally thrice weekly (every Monday, Wednesday, and Friday) during a 28-d cycle. The primary objective determined the maximum tolerated dose (MTD); secondary end-points included toxicity, pharmacokinetics, pharmacodynamics, and antitumour activity. Thirty-five patients received LY900009 at dose levels ranging from 2-60 mg. Study drug-related adverse events were diarrhoea (46%), vomiting (34%), anorexia (31%), nausea (31%), and fatigue (23%). At 30 mg, a dose-limiting toxicity (grade III mucosal inflammation) was observed. LY900009 absorption was rapid, with median tmax at 1-4 h post-dose. LY900009 inhibited plasma levels of amyloid-β peptide in a dose-dependent manner with 80-90% inhibition observed in the 30- to 60-mg cohorts. No responses...Continue Reading

Associated Clinical Trials

References

Jun 15, 1995·Statistics in Medicine·S N GoodmanS Piantadosi
Sep 30, 1994·Statistics in Medicine·E L KornR M Simon
Dec 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·A Sharma, W J Jusko
Apr 29, 1998·Cancer Chemotherapy and Pharmacology·S PiantadosiS Grossman
Apr 30, 1999·Science·S Artavanis-TsakonasR J Lake
Jul 10, 1999·Statistics in Medicine·J M Heyd, B P Carlin
Oct 23, 2003·Nature Reviews. Cancer·Freddy Radtke, Kenneth Raj
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Aug 10, 2007·Cellular and Molecular Life Sciences : CMLS·U Koch, F Radtke
Mar 25, 2008·Carcinogenesis·Benjamin W PurowHoward A Fine
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 25, 2010·Current Protein & Peptide Science·Zhiwei WangFazlul H Sarkar
Oct 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yasuhiro Funahashi
Aug 25, 2012·Biochimica Et Biophysica Acta·Carolina N Perdigoto, Allison J Bardin
Sep 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Shannon M McAuliffeDaniela M Dinulescu
Oct 1, 2013·Pharmacology & Therapeutics·Naoko TakebeSherry X Yang

❮ Previous
Next ❯

Citations

Apr 6, 2016·Journal of Medicinal Chemistry·Rajesh KumarDela Golshayan
Mar 10, 2017·Expert Opinion on Investigational Drugs·Fabio BarraSimone Ferrero
Mar 30, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shivaani KummarAlice P Chen
May 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R FerrarottoP Munster
Jul 31, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MassardJ Rodon
Aug 14, 2018·The Journal of Pathology·Victor Ljl ThijssenArjan W Griffioen
Jul 16, 2019·Expert Opinion on Therapeutic Targets·Giorgio AquilaAnna Malaschicheva
Apr 10, 2020·Journal of Neurology·A Zachou, E Anagnostou
Feb 13, 2018·Experimental and Therapeutic Medicine·Nuray ErinBülent Yildirim
May 31, 2018·Critical Reviews in Food Science and Nutrition·Parisa RahimiAlireza Ostadrahimi
Mar 31, 2017·Stem Cells International·Jeffrey KouryJijun Hao
Aug 9, 2018·Frontiers in Oncology·Venus Sosa IglesiasMarc Vooijs
Nov 5, 2019·Frontiers in Oncology·Xuan ZhuXing Niu
Dec 4, 2019·Nature Reviews. Clinical Oncology·Joseph A ClaraNaoko Takebe
Apr 26, 2017·Current Treatment Options in Oncology·Javier Martínez TruferoRoberto Pazo Cid
Dec 8, 2019·Journal of Ovarian Research·Vahideh KeyvaniMohammad Reza Abbaszadegan
Jul 7, 2020·Frontiers in Cell and Developmental Biology·Diana PáduaPatrícia Mesquita
Oct 28, 2017·Chemical Biology & Drug Design·Peter DobranowskiPeter C Black
Aug 10, 2019·World Journal of Stem Cells·Fang-Yu DuGuo-Liang Chen
Aug 18, 2020·OncoTargets and Therapy·Yucong LiQi Zhou
Aug 14, 2020·International Journal of Molecular Sciences·Amnah SharifRodrigo Fernandez-Valdivia
Sep 12, 2020·Molecular Pharmacology·Lobna Faiz GharaibehWalhan Alshaer
Feb 5, 2021·Cancers·Chie Kudo-SaitoYamato Ogiwara
Feb 20, 2021·Seminars in Cancer Biology·M CummingsN M Orsi
May 1, 2021·International Journal of Molecular Sciences·Srishti JainTracy Robson
Jun 1, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Guangxin YanZhaoyu Liu
Jun 15, 2021·Frontiers in Cell and Developmental Biology·Frederick Allen, Ivan Maillard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.